跳至主要内容
临床试验/NL-OMON34678
NL-OMON34678招募中不适用

The significance of biomarkers in the blood in the diagnosis and the course of Alzheimer*s disease - Blood biomarkers for Alzheimer*s disease

niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Patient inclusion criteria:
  • - Patients with Alzheimer's disease
  • - Mentally competent AD patient [Clinical Dementia Rating (CDR) scale 1]
  • - The diagnosis of probable Alzheimer's disease* should be made according to the NINCDS-
  • ADRDA criteria.
  • - Patients or carers should agree with the study (written informed consent is required form
  • patients or their carers).;Inclusion criteria control group (healthy subjects in group A):
  • - Men or women without cognitive or psychiatric disorders
  • - Mini-Mental State Examination (MMSE) score >= 28

排除标准

  • Patient exclusion criteria:
  • - Mentally incompetent AD patient [Clinical Dementia Rating (CDR) scale 2 and 3]
  • - Patients with infection or inflammatory disease less than 1 months ago.
  • - Patients with active malignancy.
  • - Patients with autoimmune disease (e.g. temporal arteritis, polymyalgia rheumatica).
  • - Patients who use immune modulating drugs (e.g. Immunocyanin, interferon gamma, immunoglobulin).
  • - Patients with renal dysfunction (MDRD <50)
  • - Patients with liver impairment
  • - Patients with decreased serum albumin <25 g / l;Exclusion criteria control group:
  • - Conform the patient exclusion criteria

研究者

发起方
niversitair Medisch Centrum Sint Radboud

相似试验

The significance of biomarkers in the blood in the... | 临床试验